多靶点血液检测用于肝细胞癌早期检测:ALTUS前瞻性研究的横断面分析
ALTUS前瞻性多中心研究在美国纳入肝硬化或慢性HBV感染且符合常规HCC筛查条件的成人,头对头比较多靶点HCC血液检测(mt-HBT)与标准超声。但mt-HBT特异性81.8%未达预设82%目标。
要点
- mt-HBT对早期HCC敏感性66.7%,显著高于超声的22.2%。
- mt-HBT特异性81.8%,未达到预设的82%目标。
- 超声特异性98.6%,任何分期HCC敏感性29.7%。
核心结论
- mt-HBT对早期HCC的观察敏感性高于超声,配对绝对差异44.4%(95%CI 20.2-63.8%),但特异性未达预设目标。
研究设计与样本
- 前瞻性多中心研究,2021年7月至2025年6月在美国开展,纳入肝硬化或慢性HBV感染且符合常规HCC筛查的成人。
- 所有参与者以CT或MRI为参考标准,共3089例入组,2293例有配对的超声与mt-HBT结果可评估。
主要发现
- 早期HCC敏感性:mt-HBT为66.7%(95%CI 47.8-81.4%),超声为22.2%(95%CI 10.6-40.8%),确认mt-HBT在预设5%界值内非劣效。
- mt-HBT特异性为81.8%(95%CI 80.1-83.4%),未达到预设的共同主要结局82%;超声特异性为98.6%(95%CI 98.0-99.0%)。
- 任何分期HCC敏感性:mt-HBT为73.0%(95%CI 57.0-84.6%),超声为29.7%(95%CI 17.5-45.8%)。
- 采血过程中未发生严重不良事件。
关键数值与推荐
- 早期HCC敏感性非劣效界值为5%,mt-HBT达到非劣效并进一步检验优效性。
- mt-HBT特异性共同主要结局预设目标为82%,实际81.8%未达标。
临床怎么用
- mt-HBT对早期HCC敏感性明显高于超声,但特异性偏低,需进一步评估血液检测作为影像筛查补充或替代的可行性。
- 超声对早期HCC敏感性有限,尤其在肥胖和脂肪性肝病人群中,血液检测可能有助于弥补这一不足。
局限性
- 本研究为横断面分析,早期HCC病例数较少(27例),敏感性置信区间较宽。
- mt-HBT特异性未达到预设目标,需在更大样本中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Globally, 350 million people are at risk for HCC. Ultrasound screening is recommended but is limited by poor sensitivity for early-stage HCC and low adherence. This study evaluated whether the multi-target HCC blood test (mt-HBT) demonstrates non-inferior sensitivity for early-stage HCC compared with ultrasound and assessed its specificity. METHODS: This prospective, multicenter study, conducted between July 2021 and June 2025 in the US, evaluated the performance of the mt-HBT in a head-to-head comparison with standard-of-care ultrasound among adults with cirrhosis or chronic HBV infection who were eligible for routine HCC screening. All participants underwent CT or MRI as the reference standard. The co-primary outcomes were non-inferiority of mt-HBT to ultrasound for early-stage HCC sensitivity, with sequential testing of superiority, and mt-HBT specificity. A secondary outcome was overall (any-stage) mt-HBT sensitivity. RESULTS: Of 3,089 participants, 2,293 were evaluable with paired ultrasound and mt-HBT results. Thirty-seven HCCs were identified, with 27 classified as early stage by Milan criteria. Early-stage HCC sensitivities were 66.7% (95% CI 47.8-81.4%) for mt-HBT and 22.2% (95% CI 10.6-40.8%) for ultrasound, confirming mt-HBT non-inferiority within the prespecified 5% margin. The specificity of mt-HBT was 81.8% (95% CI 80.1-83.4%), which did not meet the pre-specified co-primary outcome of 82%. Ultrasound specificity was 98.6% (95% CI 98.0-99.0%). Any-stage HCC sensitivity was 73.0% (95% CI 57.0-84.6%) for mt-HBT and 29.7% (95% CI 17.5-45.8%) for ultrasound. No serious adverse events occurred during blood collection. CONCLUSIONS: The mt-HBT had higher observed sensitivity than ultrasound for early-stage HCC, with a paired absolute difference of 44.4% (95% CI 20.2-63.8); however, specificity did not meet the prespecified target. IMPACT AND IMPLICATIONS: Hepatocellular carcinoma (HCC) screening remains limited by the suboptimal sensitivity of ultrasound, particularly among patients with obesity and steatotic liver disease. In this prospective multicenter study, a multi-target HCC blood test demonstrated substantially higher sensitivity for early-stage HCC detection than ultrasound while maintaining favorable screening performance across diverse patient subgroups. These findings are important for clinicians, researchers, and patients because they support further evaluation of blood-based approaches to address known limitations of imaging-based screening. TRIAL REGISTRATION: The trial is registered with ClinicalTrials.gov (NCT05064553).
引用
- John BV, Camardo M, Singal AG, et al. Multi-target blood test for hepatocellular carcinoma early detection: A cross-sectional analysis of the prospective ALTUS study. J Hepatol. 2026. PMID: 42800682. doi:10.1016/j.jhep.2026.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。